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Study objective: To evaluate the contribution of body composition measurements to
clinical assessment in patients on home nasal positive-pressure ventilation for
chronic hypercapnic respiratory failure (CHRF), and their relationship to respiratory
impairment.
Methods: Patients with CHRF (restrictive lung disease (RLD), n ¼ 37; chronic
obstructive pulmonary disease (COPD), n ¼ 19), during elective yearly evaluations
underwent pulmonary function testing (forced expiratory volumes, arterial blood
gases, maximal inspiratory and expiratory pressure (PImax or PEmax)), and
bioelectrical impedance analysis to determine fat-free mass (FFM) index (kg/m2)
and body fat mass index.
Results: When compared with age- and sex-matched healthy controls, RLD patients
(OR 5.5, CI 1.9–15.6, Po0:002) and COPD (OR 5.2, CI 1.1–24.9, P ¼ 0:04) were
significantly more likely to have a low FFM index. Roughly one-half of patients with
RLD and one-third with COPD had abnormally low FFM index. Estimation of
nutritional status by body mass index (BMI) alone clearly underestimated the
prevalence of FFM index depletion. Muscle mass assessed by FFM index explained
26% of variance of PImax (Po0:001) and 27% of that of PEmax (Po0:001).
Conclusion: BMI alone clearly underestimated FFM depletion, and presence of a
very high body fat mass index. Indeed, normal or high BMI can be associated with
FFM depletion. Because of its relationship to respiratory muscle strength, an
assessment of FFM appears to be valuable in CHRF.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
372 9349; fax+41 22 372 9363.
edecine.unige.ch (C. Pichard).
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Patients with chronic hypercapnic respiratory fail-
ure (CHRF) suffer predominantly either from
restrictive lung diseases (RLD) or chronic obstruc-
tive pulmonary disease (COPD). Hypercapnia
(alveolar hypoventilation) develops either because
of decreased compliance of the lung and/or
chest wall or respiratory muscle weakness in
RLD, or because of airway obstruction and limited
airflow in COPD.1 Impaired gas exchange due
to chronic hypoventilation leads to secondary
pulmonary hypertension and cor pulmonale.2
Long-term home ventilation can reverse to
some extent the symptoms of chronic alveolar
hypoventilation.
CHRF causes intolerance to physical efforts and
limitations in daily activity. It also may result in an
imbalance between food intake and nutritional
needs in patients. The etiology of nutritional
alterations in CHRF is multi-factorial, and includes
increased metabolic cost of breathing, altered
metabolism in COPD patients3 and presence of
inflammatory mediators. Furthermore, corticoster-
oids promote protein catabolism and muscle
atrophy.4
Under- and over-nutrition can affect both the
physical performance and survival of CHRF pa-
tients5 and lead to quantitative and functional
alterations of skeletal and respiratory muscles.6,7
Changes in muscle mass are closely associated with
decreased respiratory strength in COPD patients.8
Furthermore, nutritional status, as assessed by
body mass index (BMI) and bioelectrical impedance
analysis (BIA), has been shown to be predictive of
respiratory muscle strength (BIA-derived fat-free
mass (FFM) having a higher predictive value
than BMI).9 Thus, the evaluation of FFM and
body fat in CHRF patients can help in adapting
nutrition support, e.g. nutrition support in malnu-
trition and food restriction in obesity. Recent
advances in body composition include the develop-
ment of easy, non-invasive, and inexpensive
bedside techniques, e.g. BIA, for the determination
of FFM.10
Because respiratory muscle strength is critical in
patients on home nasal positive-pressure ventila-
tion (NPPV) for CHRF, and may be related to
dependence on ventilatory support, the purpose
of this study was to perform body composition
measurements in these subjects, to determine the
relationship of body composition to ventilatory
function, and the additional contribution of FFM
and body fat measurement to simple indices such as
BMI in the evaluation of nutritional status and
muscular mass.Subjects and methods
All patients who are under home NPPV therapy in
our center undergo standardized yearly medical
evaluations, including measurement of pulmonary
function tests, arterial blood gases (ABG), maximal
inspiratory and expiratory mouth pressures, and
dyspnea. Body composition measurements were
performed during these yearly medical evaluations,
with patients being in stable clinical condition.
Fifty-six patients on home NPPV for CHRF, who were
routinely assessed, were prospectively included in
this study. Patients with obesity-hypoventilation
syndrome (n ¼ 38) were excluded from this analy-
sis. Patients were classified as having RLD (n ¼ 37)
or COPD (n ¼ 19). The RLD group included 26
patients with neuromuscular diseases, including
post-poliomyelitis syndrome and 11 with predomi-
nantly chest wall disease (kyphoscoliosis or seque-
lae of tuberculosis). Patient follow-up (range 5–36
months) consisted of regular home visits by
registered nurses and outpatient consultations.
For all patients, implementation of NPPV therapy
was subject to approval by a panel of experts from
the Swiss Respiratory Society, a prerequisite for
coverage by medical insurance.
Follow-up measurements were performed at 1, 2
and 3 years after initiation of NPPV. Because
decision of initiating NPPV was most often related
to an episode of acute respiratory failure, pre-NPPV
data were not available for most subjects.
This protocol was accepted by the Ethics Com-
mittee of Geneva University Hospital and informed
consent was obtained from all patients.
Control population
Healthy men (n ¼ 33) and women (n ¼ 25) from the
Geneva database (n ¼ 5635 healthy adults, age
15–98 years)11 served as control group, matched for
age (72 years), gender and height (72 cm).
Pulmonary function tests
Forced expiratory volumes (i.e. FEV1, FVC, FEV1/
FVC ratio) were measured as recommended by the
American Thoracic Society standards and are
expressed as percentage of predicted.12 Severe
ventilatory impairment was defined as FEV1o50%.
Pulmonary muscle strength was determined by
measuring maximal inspiratory pressure (PImax) at
residual volume and maximal expiratory pressure
(PEmax) at total lung capacity using a mouth
pressure meter (Micro Medical Ltd., Gillingham,
UK). For each patient, the two best values obtained
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Table 1 Anthropometric and body composition characteristics of healthy controls and patients with restrictive
lung disease (RLD) or chronic obstructive pulmonary disease (COPD) on NPPV.
Men Women
Controls RLD COPD Controls RLD COPD
n 33 20 11 25 17 8
Age (years) 61.2714.4 61.8715.8 60.8714.4 64.4714.8 63.3717.6 68.679.4
Height (cm) 170.578.3 169.579.2 171.479.6 154.877.5 153.5710.1 160.378.7
Weight (kg) 72.4712.7 67.5713.0 77.7712.9y 59.577.6 52.0712.3* 67.4716.6y
BMI (kg/m2) 24.873.6 23.574.1* 26.674.5 25.073.8 22.376.2* 26.476.7
% Ideal body
weight
106.5714.6 99.7717.9 114.1718.9y 107.1714.7 86.9719.7* 115.7728.6y
FFM (kg) 55.576.6 49.978.5* 55.277.5 39.774.1 33.576.0* 41.277.0y
FFM index (kg/
m2)
19.171.8 17.372.4* 18.872.3 16.671.6 14.373.0* 16.172.9
Body fat (kg) 16.977.3 17.678.8 22.577.7* 19.875.0 18.578.4 26.2710.0*
Body fat mass
index (kg/m2)
5.872.3 6.273.1 7.872.7* 8.472.5 8.074.0 10.373.9
Body fat (%) 22.676.3 24.9711.0 28.477.0* 32.875.4 34.079.9 37.875.9*
BMI ¼ body mass index, IBW ¼ ideal body weight, FFM ¼ fat-free mass, FFMI ¼ fat-free mass index, BF ¼ body fat, BFMI ¼ body
fat mass index.
Mean7SD, unpaired t-test between volunteers and patients, *Pp0:05; between restrictive syndrome and COPD, yPp0:05.
U.G. Kyle et al.246that matched within 10% were used. Percentage of
predicted values of PImax and PEmax were calculated
as reported by Wohlgemuth et al.13 A 6-min walk
test, feasible in 42 patients (28 RLD, 14 COPD), was
performed in a 50m corridor,14 and is reported as %
predicted.9Anthropometric measurements and
bioelectrical impedance analysis
Body height was measured to the nearest 0.5 cm
and body weight was measured to the nearest
0.1 kg on a balance beam scale. Body composition
was determined by 50 kHz BIA (Bio-Zs, Spengler,
Paris, France) as previously described15 and vali-
dated.
FFM was calculated using a validated multiple
regression BIA equation: FFM ¼ 4.104+(0.518
height2/resistance)+(0.231weight)+(0.130reactan-
ce)+(4.229sex (men ¼ 1, women ¼ 0)). Using this
regression, a previous study of BIA compared to DXA
showed a highly significant correlation between
both methods (r ¼ 0:986, SEE ¼ 1.72 kg, technical
error 1.74 kg). This BIA equation has also been
validated in healthy elderly subjects16 and lung
transplant recipients.17
FFM index and body fat mass index facilitate
body composition interpretation by normalizing for
differences in height. FFM index and body fat mass
index were calculated as FFM or body fat divided byheight2 (kg/m2). Cut-off values for the various
classifications were derived from regression equa-
tions from our database of healthy subjects
(n ¼ 5635).18 Low, normal, high or very high FFM
index or body fat mass index correspond to World
Health Organization categories19 of low
(BMIo19.9 kg/m2), normal (BMI 20.0–24.9 kg/m2),
overweight (BMI 25–29.9 kg/m2) and obese
(BMIX30 kg/m2. FFM index at these levels have
previously been shown to be associated with
nutritional risk.
Patients were considered as having an abnormal
nutritional status if FFM index was low (p17.4
(men) andp15.0 (women)); or body fat mass index
was very high (X8.2 (men) and X11.8 (women)).Statistical analysis
Descriptive statistics (Statview, Abacus Concepts;
Piscataway, NJ) were calculated for height, weight,
body composition and respiratory parameters and
are expressed as mean7standard deviation (x7SD).
Unpaired t-tests were used to test for differences
between control population and patients, and
between RLD and COPD patients. Wilcoxon singed
rank test was used for non-normally distributed
data.
Logistic regression analysis was used to estimate
odds ratios (OR) for body composition parameters
between controls and patients, and between levels
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Body composition in respiratory failure 247of ventilatory impairment (FEV1X50 versuso50%).
Patients were considered as having an abnormal
nutritional status if FFM index was low or body fat
mass index was very high. OR with 95% confidence
intervals (CI) describe the magnitude of effects for
each level of the study variables compared with the
reference category. Statistical significance was set
at Pp0:05 for all tests.Figure 1 Prevalence (%) of body mass index (BMI), fat-
free mass (FFM) index and body fat mass index.
Prevalence (%) of low, normal, high and obese BMI
(top), low, normal and high FFM index (middle), and
low, normal, high and very high body fat mass index
(bottom) in male (left) and female (right) controls and
restrictive lung disease (RLD) and chronic obstructive
pulmonary disease (COPD). w2: BMI: men P ¼ 0:14,
women P ¼ 0:01; FFM index: men P ¼ 0:02, women
P ¼ 0:03; body fat mass index: men P ¼ 0:06, women
P ¼ 0:11. FFM index (kg/m2) was considered ‘‘low’’ if
p17.4 (men) andp15.0 (women); ‘‘normal’’ if 17.5–19.7
(men) and 15.1–16.6 (women); ‘‘high’’ if X19.8 (men)
and X16.7 (women). Body fat mass index (kg/m2) was
considered ‘‘low’’ if p2.4 (men) and p4.8 (women);
‘‘normal’’ if 2.5–5.1 (men), 4.9–8.2 (women); ‘‘high’’ if
5.2–8.1 (men), 8.3–11.7 (women); ‘‘very high’’ if X8.2
(men) and X11.8 (women).Results
Body composition
Anthropometric characteristics are shown in
Table 1. BMI, and FFM index were significantly
lower in RLD than in healthy controls. Body fat mass
index and % body fat were significantly higher in
COPD (except for body fat mass index in women)
than in controls.
FFM index and body fat mass index were more
sensitive to detect decreased muscle mass or
excess body fat (Fig. 1). Indeed, 55% of male and
59% of female RLD patients fell in the low FFM
index category while only 20% and 41%, respec-
tively, had a low BMI. In COPD, 27% of male and 37%
of female patients had a low FFM index, compared
to 9% and 25% falling in the low BMI category. Thus,
BMI clearly underestimated the incidence of FFM
depletion in RLD and COPD patients (w2: 26.7 and
17.2, respectively, Po0:005).
Patients also had higher than expected body fat
mass index. Thirty-five percent of male RLD and
55% of male COPD patients fell in the very high
body fat mass index category compared to 0% and
18%, respectively, being obese by BMI (Fig. 1). BMI
therefore also underestimated the prevalence of
excess body fat in male RLD and COPD patients (w2:
34.6 and 22.1, respectively, Po0:001). Similar
underestimations of low FFM and excess body fat
were noted at 3-year follow-up (data not shown).
RLD were significantly more likely to have a low
FFM index than controls (Po0:001). COPD patients
were significantly more likely than controls to have
either a low FFM index or a high body fat mass
index (Po0:02) (Table 2).
Follow-up data at 3 years (n ¼ 21) showed that
changes for body weight, FFM index and body fat
mass index were non-significant (repeated mea-
sures ANOVA, P40:05; body weight:+1.075.1 kg;
FFM:0.272.7 kg; body fat: +1.173.7 kg), which
suggests that these parameters were stable during
long-term NPPV (data not shown). Data at 3 years is
missing in patients due to: for RDL: death (n ¼ 8),
non-compliance with NPPV (n ¼ 2), and refusal ofeither NPPV or follow-up exam (n ¼ 12); for COPD:
death (n ¼ 1), lung transplantation (n ¼ 3), non-
compliance with NPPV (n ¼ 3), and refusal of either
NPPV or follow-up exam (n ¼ 6).
ARTICLE IN PRESS
Table 2 Odds ratio (95% CI) for low, compared to healthy controls, fat-free mass (FFM) index and very high,
compared to normal, body fat mass index in patients with restrictive lung disease (RLD) or chronic obstructive
pulmonary disease (COPD) on NPPV.
% (n) % (n) OR (95% CI) P
FFM index Normal Low
Controls (n ¼ 94) 94.8 (55) 5.2 (3) 1
Patients (94)
Restrictive lung disease 48.6 (18) 51.4 (19) 19.4 (5.1–73.1) o0.001
Chronic obstructive pulmonary disease 73.7 (14) 26.3 (5) 6.5 (1.4–30.8) 0.017
Body fat mass index Normal Very high
Controls 81.3 (26) 18.7 (6) 1
Patients
Restrictive lung disease 59.1 (13) 40.9 (9) 3.0 (0.9–10.3) 0.08
Chronic obstructive pulmonary disease 30.8 (4) 69.2 (9) 9.8 (2.2–42.6) 0.003
Logistic regressions: OR ¼ odds ratio, CI ¼ confidence interval.
U.G. Kyle et al.248Pulmonary function tests
Respiratory parameters are shown in Table 3. There
were no gender differences for respiratory para-
meters: thus, combined data is shown. PImax,
PEmax, PaCO2 and 6-min walking test did not differ
significantly between RLD and COPD patients.
Sixty-seven percent of patients with RLD and 83%
of COPD had PaCO2 values above 45mm Hg without
ventilatory support at baseline.
Follow-up measurements did not change signifi-
cantly after 3 years for FEV1%, PaCO2 and 6-min
walk tests in RLD and for all respiratory parameters
in COPD. In RLD patients, FCV% and PImax%
decreased marginally, although significantly, and
consequently FEV1/FVC% increased when compared
to baseline (Wilcoxon rank test Po0:05) (Table 3).
Significant positive correlations were found
between FFM index and PImax (r ¼ 0:51; Po0:001),
PEmax (r ¼ 0:52; Po0:001) (Fig. 2), FVC % predicted
(r ¼ 0:37; Po0:007); and, to a lesser extent, be-
tween BMI and PImax (r ¼ 0:35; P ¼ 0:014), PEmax
(r ¼ 0:40; P ¼ 0:006), but not between body com-
position parameters and FEV1, PaCO2 or 6-min
walking test. The 6-min walk test was significantly
correlated only with FEV1 (r ¼ 0:31; Po0:05). There
were no significant correlations between changes in
respiratory parameters at 3 years and changes in
FFMI or body fat mass index at 3 years.
There was a trend toward an association between
low vs. normal FFM index and presence of a severe
ventilatory impairment (FEV1o50% compared
450%) (OR 4.8, CI 0.9–24.8, P ¼ 0:06). Very high
vs. normal body fat mass index (OR 1.6, 95% CI
0.2–13.2), low vs. normal BMI (OR 0.6, 95%
CI 0.1–5.4) or high vs. normal BMI (OR 1.6, 95% CI0.1–17.4) were not associated with severe ventila-
tory impairment (FEV1o50%).Discussion
We report the results of an observational study of
patients with either restrictive or obstructive lung
disease with CHRF necessitating long-term NPPV.
The very low values for FEV1 and high values for
PaCO2 in COPD and RLD (Table 3) illustrate the
severity of the ventilatory impairment in these
patients. Data presented show that measuring FFM
index and body fat mass index by BIA provided
information that could not be extrapolated from
BMI only. Relying on BMI alone clearly under-
estimated FFM depletion as well as presence of a
very high body fat mass index. Both RLD and COPD
patients had a higher probability of having muscle
mass depletion (low FFM index) and/or excess body
fat than healthy controls. Interestingly, FFM index
and indexes of respiratory muscle strength (PImax or
PEmax) were significantly correlated, FFM explain-
ing 26–27% of the variance of respiratory muscle
strength (Fig. 2), and suggesting a relationship
between decrease in peripheral muscle mass and
respiratory muscle function.
Body composition
A substantial proportion of RLD patients (55%) were
muscle depleted at the time of inclusion into this
study. The lower FFM index found in RLD is not
surprising since these patients have an amyotrophy
due either to their neuromuscular disease, or to
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Figure 2 Correlations between PImax (top) and PEmax
(bottom) and fat-free mass (FFM) index in patients with
restrictive lung disease (RLD) and chronic obstructive
pulmonary disease (COPD).
U.G. Kyle et al.250low physical activity levels (6-min walking tests at
55% of predicted values).
The COPD group included more ‘‘Blue Bloaters’’
than ‘‘Pink Puffers’’ with a high BMI and body fat
mass index and normal or high FFM index noted in
the former and low values in the latter. However,
even though mean FFM index in COPD did not differ
from healthy controls (Table 1), COPD patients
were significantly more likely to have low FFM
index than controls (Fig. 1): 31% of COPD had a low
FFM index. Decreased FFM, measured by BIA, was
noted by Cano et al.5 in 53.6% of RLD or COPD
patients treated by LTOT and/or home mechanical
ventilation, while only 23.2% had a BMIo20 kg/m2.
Our study agrees with Cano et al.5 and Soler et al.20
in that BMI underestimates the prevalence of FFM
depletion, which is highly prevalent in chronic
respiratory failure.
Low FFM index may be due to high energy
expenditure, low food intake, low physical activity,
low protein synthesis and/or high protein break-down due to drug therapy (i.e. cortisone) or
presence of cytokines;3,22–24 it may result from
amyotrophy secondary to neuromuscular abnorm-
alities or respiratory insufficiency. In COPD, hypo-
gonadism and decreased levels of IGF-1 have also
been implicated.25 Increased energy expenditure
has been reported in both RLD and COPD; it may
result from increased work of breathing, and
contribute to a progressive decline in FFM. A
number of our RLD and COPD patients (19% and
11%, respectively) had both low FFM index and high
or very high body fat mass index, which suggests
that energy intake was adequate, but muscle
accretion did not occur due to either disuse or
above-mentioned metabolic abnormalities.
The association between FFM and indexes of
respiratory muscle function (PImax or PEmax) found
in our study in RLD and COPD, and shown by
others,9 suggests a general reduction in skeletal
muscle function, rather than a problem limited
purely to the respiratory muscles and further
suggests that factors other than disuse may
negatively influence muscle strength in COPD.26
For patients with restrictive lung disorders related
to neuromuscular diseases, progressive amyotrophy
may involve respiratory muscles and explain the
correlation between peripheral muscle mass, and
PImax or PEmax. Conversely, in moderate to severe
COPD, it has been suggested that strength and
inspiratory action of the diaphragm were not
altered; furthermore, muscle adaptation in mod-
erate COPD (increase in oxidative capacity, and in
number of type I fibers) occurs earlier in the
diaphragm than in peripheral muscles (vastus
lateralis).27 A shortening in the length of sarco-
meres and an increase in the concentration of
mitochondria has also been described in severe
COPD (samples obtained during thoracotomy),
which should in fact contribute to improve muscle
function.28 Decreased levels of PImax or PEmax may
thus reflect mainly geometric changes in respira-
tory mechanics more than muscular dysfunction or
atrophy. However, decrease in diaphragmatic mass
and strength associated with malnutrition have
been reported in earlier anatomic-pathological
studies, suggesting a possible causal relation-
ship between decreased FFM index and PImax or
PEmax.
29,30
Intermittent ventilatory support could have a
negative impact on respiratory muscle mass and
function by inducing disuse muscle atrophy.
Although a decrease in respiratory muscle mass is
possible in continuous and prolonged mechanical
ventilation, this has, to our knowledge, never been
described in long-term intermittent NPPV.31 In this
study, the stability of FFM index and the absence of
ARTICLE IN PRESS
Body composition in respiratory failure 251clinically significant changes in PEmax and PImax over
3 years (Table 3) suggests preservation of respira-
tory muscle mass and function in patients who were
followed up for 3 years.Study limitations
This observational study of body composition in
severe CHRF was not designed to explore the
possible biological causative mechanisms contribut-
ing to muscle mass depletion in this population.
The high dropout rate at follow-up (62%, because of
death, lung transplantation, or non-compliance)
limits generalization of results with regard to
stability of respiratory muscle function and pre-
servation of FFM.
Also, speculation as to a physiological relation-
ship between FFM index and respiratory muscle
strength is limited by the technique used to assess
respiratory muscle strength: although widely used
in clinical practice, PImax or PEmax do not only
reflect respiratory muscle strength but are influ-
enced by airway resistance (dampening of trans-
mission of pressure changes in severe airway
obstruction) and geometric changes related to
hyperinflation or kyphoscoliosis; for these reasons,
in COPD, PImax tends to underestimate esophageal
pressure.32Conclusions
The present results suggest that the analysis of
body compartments to quantify FFM in patients
with CHRF on NPPV is more informative than the
use of BMI alone. Because of the numerous
mechanisms that can lead to FFM depletion in
chronic respiratory failure, adequate monitoring of
body composition appears warranted. Indeed,
normal or high BMI can be associated with FFM
depletion. The present data also showed a sig-
nificant correlation between low FFM index and
impaired respiratory muscle strength. In spite of
the above-mentioned limitations, FFM index may
prove useful for explaining inspiratory muscle
dysfunction leading to increased dependence on
ventilatory support in CHRF.Acknowledgment
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